Dr. Jeffrey M. Clarke
Claim this profileDuke Cancer Institute
Area of expertise
Lung Cancer
Jeffrey M. Clarke has run 7 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Jeffrey M. Clarke has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Duke Cancer Institute
Duke University Medical Center
Clinical Trials Jeffrey M. Clarke is currently running
Pre-Surgery Immunotherapy
for Mesothelioma
This trial tests if giving immunotherapy drugs can better control disease in patients with a specific type of mesothelioma. The drugs help the immune system attack cancer cells, which may stop the cancer from growing and spreading.
Recruiting
1 award
Phase 2
27 criteria
Chemoimmunotherapy
for Mesothelioma
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM. Primary Objectives: The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy. Secondary Objective(s): The secondary objectives are to determine the safety of and whether the platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves response rate, resectability, major pathological response, and complete pathological response. Exploratory Objective(s): The exploratory objectives are to determine the safety of and whether the platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves response rate, resectability, major pathological response, and complete pathological response for patients with epithelioid and non-epithelioid histologies. The scientific exploratory objectives include: 1. Develop an NGS plasma assay of common mutations identified from our previous grant cycle to prospectively measure minimal residual disease (MRD) after resection as a potential, novel biomarker test in mesothelioma. 2. Determine the predictive role of BH3 profiling in patients undergoing neoadjuvant ICI followed by surgery: With patient samples collected from our neoadjuvant ICI trial, the investigators will test whether BH3 profiling from pre-treatment tumor biopsies and PBMC predicts clinical, radiological, and pathological responses to ICIs. The investigators will identify TAMs from the TiME in MPM tumor samples before and after treatment to compare differences in polarization induced by ICI in clinical and pathologically responding versus non-responding patients.
Recruiting
1 award
Phase 1 & 2
10 criteria
More about Jeffrey M. Clarke
Clinical Trial Related
3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jeffrey M. Clarke has experience with
- Pembrolizumab
- GT103
- Nivolumab
- Durvalumab
- Tremelimumab
- Platinum Cisplatin Or Carboplatin And Pemetrexed Chemotherapy
Breakdown of trials Jeffrey M. Clarke has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey M. Clarke specialize in?
Jeffrey M. Clarke focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jeffrey M. Clarke currently recruiting for clinical trials?
Yes, Jeffrey M. Clarke is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey M. Clarke has studied deeply?
Yes, Jeffrey M. Clarke has studied treatments such as Pembrolizumab, GT103, Nivolumab.
What is the best way to schedule an appointment with Jeffrey M. Clarke?
Apply for one of the trials that Jeffrey M. Clarke is conducting.
What is the office address of Jeffrey M. Clarke?
The office of Jeffrey M. Clarke is located at: Duke Cancer Institute, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.